ResMed Valuation Overview

RMD -- USA Stock  

USD 107.03  0.90  0.83%

ResMed holds recent Real Value of $84.63225 per share. The prevailing price of the company is $107.03. At this time the company appears to be over valued. Macroaxis determines value of ResMed from analyzing the company fundamentals such as Shares Outstanding of 142.74M, Operating Margin of 28.09% and Return On Equity of 15.29% as well as examining its technical indicators and Probability Of Bankruptcy. In general, we support investing in undervalued entities and to dispose of overvalued entities since at some point stocks prices and their ongoing real values will merge together.

Valuation Drivers Correlation

Selected ResMed Valuation Data Over Time

Net Income Per Employee    Enterprise Value    Market Capitalization    
 Time Horizon     30 Days    Login   to change
ResMed is rated second in beta category among related companies. It is rated fourth in price to book category among related companies fabricating about  5.87  of Price to Book per Beta.

Current Market Valuation

ResMed Valuation Boundaries
Over Valued
June 24, 2018
Market Value
Real Value
Target Odds
ResMed is not too risky asset. Calculation of real value of ResMed is based on 1 month time horizon. Increasing ResMed time horizon generally increases accuracy of value calculation and significantly improves predictive power of the methodology used.

Tax Efficiency

ResMed Tax Efficiency History

Tax Efficiency

Market Capitalization

ResMed Market Capitalization Analysis
ResMed is rated fourth in market capitalization category among related companies. Market capitalization of Medical Equipment industry is at this time estimated at about 219.27 Billion. ResMed holds roughly 15.28 Billion in market capitalization claiming about 7% of all equities under Medical Equipment industry.
Capitalization  Workforce  Valuation  Revenue  Total debt
Additionally take a look at Your Equity Center. Please also try Alpha Finder module to use alpha and beta coefficients to find investment opportunities after accounting for the risk.